Clarus Therapeutics Holdings Inc (NASDAQ:CRXT – Get Rating) saw a significant growth in short interest in the month of March. As of March 15th, there was short interest totalling 60,400 shares, a growth of 33.6% from the February 28th total of 45,200 shares. Approximately 0.8% of the shares of the company are sold short. Based […]
Equities research analysts expect Clarus Therapeutics Holdings Inc (NASDAQ:CRXT – Get Rating) to announce sales of $4.80 million for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for Clarus Therapeutics’ earnings. The lowest sales estimate is $4.40 million and the highest is $5.20 million. The company is expected to issue its […]
/PRNewswire/ The testosterone replacement therapy market size is expected to increase by USD 113.54 million from 2019 to 2024, registering a CAGR of almost.
/PRNewswire/ The testosterone replacement therapy market size is expected to increase by USD 113.54 million from 2019 to 2024, registering a CAGR of almost.
/PRNewswire/ Under the terms of Agreement Lipocine to receive: Up to $21.0 million in licensing fees, including $11.0 million payable immediately and $10.0.